Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
Abstract Background Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL. Meth...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13400-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594634243571712 |
|---|---|
| author | Fanqiao Meng Maoyuan Xiang Yu Liu Dongfeng Zeng |
| author_facet | Fanqiao Meng Maoyuan Xiang Yu Liu Dongfeng Zeng |
| author_sort | Fanqiao Meng |
| collection | DOAJ |
| description | Abstract Background Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL. Methods A systematic literature search of PubMed, Cochrane, Embase, ClinicalTrials.gov, and Web of Science databases was conducted until February 2024. The odds ratio (OR) with a 95% confidence interval (CI) was analysed using Review Manager 5.4. Outcomes including overall response rate (ORR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for meta-analysis. We used the Methodological Index for Non-Randomized Studies (MINORS) to evaluate the quality of the included literature. Results A total of 151 participants from 8 records were included. Meta-analysis showed the ORR of CD30 CAR-T cell therapy for R/R cHL was 57% (95%CI 0.36–0.76, P = 0.50), with a CR of 34% (95%CI 0.13–0.64, P = 0.29) and a PR of 32% (95%CI 0.15–0.55, P = 0.12). With the median follow-up range from 9.5 to 71.5 months, the 1-year PFS was 39% (95% CI 0.30–0.49, P = 0.04), and the 1-year OS was 89% (95% CI 0.65–0.97, P = 0.005). The most common hematologic AE was leukopenia (72%, 95% CI: 0.50–0.87), and the most common non-hematological AE was cytokine release syndrome (CRS) (43%, 95% CI: 0.14–0.76). The grade ≥ 3 AEs was 66% (95%CI 0.06–0.98, I2 = 93%, P = 0.70), 34% (95%CI 0.07–0.78, I2 = 85%, P = 0.51) in neutropenia and thrombocytopenia, respectively. All AEs were tolerable and resolved with treatment. Conclusion Current evidence suggests that anti-CD30 CAR-T cell therapy is effective and safe in treating R/R cHL and is worth considering as a viable therapeutic option. |
| format | Article |
| id | doaj-art-8f67f983ff9a44cabf7e2737ca4ab0f7 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-8f67f983ff9a44cabf7e2737ca4ab0f72025-01-19T12:26:47ZengBMCBMC Cancer1471-24072025-01-0125111110.1186/s12885-024-13400-5Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysisFanqiao Meng0Maoyuan Xiang1Yu Liu2Dongfeng Zeng3Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University)Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University)Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University)Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University)Abstract Background Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL. Methods A systematic literature search of PubMed, Cochrane, Embase, ClinicalTrials.gov, and Web of Science databases was conducted until February 2024. The odds ratio (OR) with a 95% confidence interval (CI) was analysed using Review Manager 5.4. Outcomes including overall response rate (ORR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for meta-analysis. We used the Methodological Index for Non-Randomized Studies (MINORS) to evaluate the quality of the included literature. Results A total of 151 participants from 8 records were included. Meta-analysis showed the ORR of CD30 CAR-T cell therapy for R/R cHL was 57% (95%CI 0.36–0.76, P = 0.50), with a CR of 34% (95%CI 0.13–0.64, P = 0.29) and a PR of 32% (95%CI 0.15–0.55, P = 0.12). With the median follow-up range from 9.5 to 71.5 months, the 1-year PFS was 39% (95% CI 0.30–0.49, P = 0.04), and the 1-year OS was 89% (95% CI 0.65–0.97, P = 0.005). The most common hematologic AE was leukopenia (72%, 95% CI: 0.50–0.87), and the most common non-hematological AE was cytokine release syndrome (CRS) (43%, 95% CI: 0.14–0.76). The grade ≥ 3 AEs was 66% (95%CI 0.06–0.98, I2 = 93%, P = 0.70), 34% (95%CI 0.07–0.78, I2 = 85%, P = 0.51) in neutropenia and thrombocytopenia, respectively. All AEs were tolerable and resolved with treatment. Conclusion Current evidence suggests that anti-CD30 CAR-T cell therapy is effective and safe in treating R/R cHL and is worth considering as a viable therapeutic option.https://doi.org/10.1186/s12885-024-13400-5Hodgkin lymphomaCD30CAR-TSystematic review |
| spellingShingle | Fanqiao Meng Maoyuan Xiang Yu Liu Dongfeng Zeng Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis BMC Cancer Hodgkin lymphoma CD30 CAR-T Systematic review |
| title | Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis |
| title_full | Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis |
| title_fullStr | Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis |
| title_full_unstemmed | Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis |
| title_short | Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis |
| title_sort | safety and efficacy of anti cd30 car t cell therapy in relapsed refractory classic hodgkin lymphoma a systematic review and meta analysis |
| topic | Hodgkin lymphoma CD30 CAR-T Systematic review |
| url | https://doi.org/10.1186/s12885-024-13400-5 |
| work_keys_str_mv | AT fanqiaomeng safetyandefficacyofanticd30cartcelltherapyinrelapsedrefractoryclassichodgkinlymphomaasystematicreviewandmetaanalysis AT maoyuanxiang safetyandefficacyofanticd30cartcelltherapyinrelapsedrefractoryclassichodgkinlymphomaasystematicreviewandmetaanalysis AT yuliu safetyandefficacyofanticd30cartcelltherapyinrelapsedrefractoryclassichodgkinlymphomaasystematicreviewandmetaanalysis AT dongfengzeng safetyandefficacyofanticd30cartcelltherapyinrelapsedrefractoryclassichodgkinlymphomaasystematicreviewandmetaanalysis |